Scleroderma
Background
- Autoimmune collagen vascular disease, aka Systemic Sclerosis
- Inappropriate and excessive accumulation of collagen and matrix in various tissues
- Widespread vascular lesions
- Endothelial dysfunction
- Vascular spasm
- Vascular wall thickening
- Narrowed lumen
- Two types, Diffuse and Limited
- Diffuse Systemic Sclerosis: Skin changes, which can progress to internal organ involvement
- Limited Cutaneous Systemic Sclerosis, aka "CREST Syndrome"
Clinical Features
- Systemic complaints (fever, malaise, fatigue, weight loss, myalgias)
- Diffuse Systemic Sclerosis
- hypo- or hyper- pigmentation of skin, extending from fingers and toes proximally, also involving chest and abdominal wall
- Pigment is perserved around hair follicles leading to salt and pepper appearance
Hypopigmentation in Diffuse Scleroderma, courtesy of Regional Derm website - Symmetric hand edema and Raynaud's phenomenon
- Abrupt Disease presentation; worse in first 18 months then improvement or worsening to involve internal organs
- Liminted Sytemic Sclerosis, aka "CREST Syndrome"
- Longstanding Raynaud's
- Skin thickening and fibrosis distal to elbows and knees, and on face
- Subcutaneous calcinosis
- Esophageal dysmotility
- Sclerodactyly
- Telangiectasia
- Indolent course
Emergencies
- Renal Crisis
- Causes are vessel narrowing and subsequent ischemic kidney disease
- Lead to hypertensive emergency, acute renal failure, and microangiopathic hemolytic anemia
- Occurs during first 5 years of the disease
- Treatment is strict BP control - ACEI drug of choice
- Was the most common cause of death prior to ACEi usage[1]
- Severe renal crisis is life threatening with incidence of 8-10% in Limited and 10-20% in diffuse
- Similar to TTP/HUS with microangiography
- Poor prognosis with sudden onset of hypertension, encephalopathy, CVA, retinopathy
- Risk factors are rapidly progressing Diffuse Scleroderma, high dose glucocorticoid use, cyclosporin therapy, presence of anti-RNA-polymerase antibodies.[2]
- Pulmonary
- Respiratory failure
- Interstitial Lung Disease, leading to pulmonary fibrosis
- Found in dorsal portion of both lower lobes, but can extend to upper lobes in severe diease
- Poor prognosis with severe pulmonary impairment. 42% die within 10 years of disease onset[3]
- ARDS
- Aspiration pneumonitis
- Pulmonary hypertension
- Gradually progressive exercise breathlessness
- Fatigue
- Anginal pain from right ventricle ischemia and low cardiac output
- Hoarseness from nerve palsy caused by dilated pulmonary artery stem
- Alveolar hemorrhage
- Hemoptysis, infiltrates on CXR, anemia.
- Emergent bronchoscopy
- High dose corticosteroids, cyclophosphamide, local vessel embolization or plasma exchange
- Cardiac
- Acute heart failure
- Can be from diastolic dysfunction, malignant hypertension during renal crisis, and decompensated pulmonary hypertension
- Cardiopulmonary complications are the most common causes of scleroderma-related death[4], with cardiac causes[5] and pulmonary fibrosis[6] being the most common.
- Acute heart failure
Differential Diagnosis
- Systemic Lupus Erythematous
- Sjogren's Syndrome
- Raynaud's Syndrome
Evaluation
- Frequent blood pressure checks
- Serologic markers for each subset
- Renal Crisis
- Urinalysis for proteinuria or hematuria
- Basic Metabolic Panel
- Chest Xray for pulmonary edema
- Pulmonary Arterial Hypertension
- Basic labs, including troponin
- Echo to evaluate right heart and estimation of right atrial pressure
- Right heart catheterization indicated in symptomatic patients
- Interstitial Lung Diease
- Frequent checks of FVC to monitor disease
- Chest xray, CT of the chest
- Lung biopsy
- CREST Syndrome
- Endoscopy and Hemoccult test to evaluate for blood loss from mucosal telangiectasias (gastric antral vascular ectasia, described as "watermelon stomach."
Management
- Renal Crisis
- Rapid control of blood pressure
- Start on ACE Inhibitor, captopril 6.25 to 12.5mg PO, TID.
- Avoid diuretics
- Consult Nephrology, as 50% of patients will require dialysis.
- Pulmonary Arterial Hypertension
- Warfarin to prevent Pulmonary Embolism
- Endothelin-I receptor antagonist, phosphodiesterase inhibitor or IV prostanoids
- Interstitial Lung Disease
- lower dose glucocorticoid
- cyclophosphamide
- May require ventilatory support (NIPPV or Intubation)
- CREST Syndrome
- Empiric treatment with a PPI to prevent reflux and stricture formation
- Blood replacement if chronic loss from mucosal telangiectasias
- Ursodial treatment if concomitant primary biliary cirrhosis to prevent progression to secondary cirrhosis
Disposition
- Hospitalization for any elevation in blood pressure, difficulty breathing, evidence of heart strain or pulmonary edema.
- Consult Rheumatology
- Consult Pulmonary
- Consult Nephrology
See Also
References
- ↑ Komocsi A, Vorobcsuk A, Faludi R, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012;51:1027–1036
- ↑ Vymetal J, Skacelova M, Smrzova A, Klicova A, Schubertova M, Horak P, Zadrazil J. Emergency situations in rheumatology with a focus on systemic autoimmune diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):20-9. doi: 10.5507/bp.2016.002. Epub 2016 Feb 10. Review. PubMed PMID: 26868300.
- ↑ Luo Y, Xiao R. Interstitial Lung Disease in Scleroderma: Clinical Features and Pathogenesis. Rheumatology 2011 doi:10.4172/2161- 1149. S1-002. Available from: http://omicsonline.org/ interstitial-lung-disease-in-scleroderma-clinical-features-and- pathogenesis-2161-1149.S1-002.pdf
- ↑ Nikpour, M., Baron, M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol. 2014;26:131–137
- ↑ Komocsi A, Vorobcsuk A, Faludi R, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012;51:1027–1036
- ↑ Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–15. doi: 10.1136/ard.2009.114264
